Acute pancreatitis in a 61-year-old man with COVID-19

Case report OA: closed
⚙ AI-generated summary by qwen3.7-flash+body, 2026-11-12 ⓘ

This case report describes a 61-year-old man who developed acute pancreatitis during recovery from severe COVID-19 pneumonia, with symptoms resolving after supportive care.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-11-12 · read from full text ⓘ

This case report describes a 61-year-old man who developed acute pancreatitis during hospitalization for severe COVID-19 pneumonia. The patient presented with abdominal pain and elevated serum lipase levels, while imaging confirmed pancreatic inflammation without evidence of gallstones or alcohol use. The authors attribute the condition to either direct SARS-CoV-2 infection via ACE2 receptors in the pancreas or as an adverse effect of medications such as tocilizumab and dexamethasone used in treatment. Relevance to endometriosis: The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 11,539 characters · extracted from oa-pdf · 3 sections · click to expand

Results

from testing of nasal and throat swabs using real-time transcription polymerase chain reaction assay were positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within 3 days of our patient’s admission to hospital, severe COVID-19 pneumonia developed,1 with tachypnea and hypoxemia that required high-flow oxygen supplementation, fever and weight loss. We initially prescribed azithromycin (500  mg daily for 3  d), hydroxychloroquine (loading dose of 800  mg on day  1, followed by 200  mg twice daily for 10  d) and zinc (50  mg twice daily for 5  d). In addition, he received acetaminophen as needed (1000  mg on 4  dif- ferent occasions). We later prescribed tocilizumab (anti-interleukin-6 receptor antibody, 2  doses of 400  mg administered intravenously), dexamethasone (10  mg twice daily administered intravenously for 5  d with tapering thereafter), enoxaparin (80  mg twice daily for 10 d), lopinavir/ritonavir (2 tablets of 200 mg/50 mg twice daily for 5 d) and pantoprazole (40 mg daily administered intravenously). A culture of his sputum identified Staphylococcus aureus, and we added ciprofloxacin (400  mg twice daily administered intra - venously) and clindamycin (300 mg administered orally 4 times a day for 7 d). Seven days later, our patient’s respiratory status had improved, and he no longer required high-flow oxygen. On day 14, our patient reported sudden diffuse abdominal pain with anorexia. He was afebrile and had no vomiting or diarrhea. His abdomen was soft, with mild diffuse tenderness but no signs of peri- toneal irritation. A complete blood cell count showed his level of leu- kocytes was elevated at 37 (normal 4.5–11.5) × 109/L with 93% neu- trophils, and he had an absolute lymphocyte count of 0.98 (normal 1.5–5.0)  × 109/L. His serum lipase level was elevated at 203  (normal 21–67) U/L, and he had a serum amylase level of 142 U/L (28–100 U/L). His levels of alkaline phosphatase and direct bilirubin were in the nor- mal range. Contrast-enhanced computed tomography (CT) of our patient’s abdomen showed signs of pancreatitis (Figure 1).2 We diag- nosed acute pancreatitis and started supportive treatment, including nothing by mouth, intravenous fluids and analgesia. Two days later, our patient’s gastrointestinal symptoms had resolved completely, and all abnormal laboratory values had returned to normal. We ran additional blood tests to investigate the cause of acute pancreatitis. 3 His levels of liver enzymes and calcium were normal. His serum level of triglycerides was mildly elevated (3.18  [normal 1.8]  mmol/L; his level was normal [< 1.69 mmol/L] 1 d before the onset of abdominal pain and was 3.46 mmol/L on the day after the contrast-enhanced CT). Imaging did not show gallstones, or abnormalities of the gallbladder or bile duct. Our patient did not have a medical history of pancrea- titis, and he had no history of heavy consumption of alcohol. PRACTICE | CASES CPD Acute pancreatitis in a 61-year-old man with COVID-19 Shay Brikman MD, Veronika Denysova MD, Husam Menzal MD, Guy Dori MD PhD n Cite as: CMAJ 2020 July 27;192:E858-9. doi: 10.1503/cmaj.201029 KEY POINTS • Acute pancreatitis has been associated with severe coronavirus disease 2019 (COVID-19). • Medications used to manage severe COVID-19 have been associated with acute pancreatitis. • Unresolved abdominal pain occurring late in the course of COVID-19 warrants a thorough work-up, which may include testing for levels of amylase, lipase, liver enzymes and triglycerides, and abdominal computed tomography. Figure 1: Abdominal contrast-enhanced computed tomography in a 61-year-old man recovering from severe coronavirus disease 2019 pneu- monia that shows signs of acute pancreatitis, including focal parenchy- mal enhancement of the pancreas head with inflammatory changes in peripancreatic fat (red arrow). PRACTICE CMAJ | JULY 27, 2020 | VOLUME 192 | ISSUE 30 E859

Discussion

Acute pancreatitis is an inflammatory disorder of the pancreas, most commonly caused by gallstones and heavy alcohol con- sumption. 4 The revised Atlanta classification system defines acute pancreatitis if at least 2 of the following 3 criteria are met in a patient: abdominal pain (acute onset of persistent and severe epigastric pain); increased serum lipase (or amylase) lev- els to greater than 3  times the upper limit of normal value; or characteristic findings of acute pancreatitis on contrast enhanced CT.2 Our patient met 2 out of 3 criteria, as his elevated lipase level did not exceed 3  times the upper limit of normal value. We propose that our patient’s acute pancreatitis was most likely related to infection with SARS-CoV-2, medication used to manage the infection or a combination of both. Up to 10% of acute pancreatitis is thought to have an infec- tious cause (mostly viral; e.g., mumps, coxsackievirus or cyto- megalovirus) either through direct viral injury or through an immune-mediated inflammatory response. 5 The SARS-CoV-2 Spike protein binds angiotensin-converting enzyme 2 (ACE2) pro- tein of the host cell membrane to fuse into the cell for viral repli- cation. Angiotensin-converting enzyme-2 is highly expressed on lung alveolar epithelial cells;6 however, overexpression of ACE2 in the pancreas has been reported recently.7 Our patient’s presentation and onset of symptoms is consis - tent with previous findings that 17% of patients with severe COVID-19 have pancreatic injury with elevated serum amylase and lipase, and as many as 7% of patients have imaging findings compatible with pancreatitis. 7,8 A case report involving 3  mem- bers of the same family who were admitted to hospital in Den- mark found 2 cases of acute pancreatitis associated with COVID- 19, both shortly after admission and with plasma levels of amylase over 900 U/L. 9 In a letter to the editor of the British Jour- nal of Surgery, Anand and colleagues reported a case involving a 59-year-old woman with COVID-19 in the United Kingdom who had acute pancreatitis 10 days after admission to hospital, which was complicated by bacterial pneumonia. She was treated with intravenous vancomycin and a course of doxycycline.10 Drug-related acute pancreatitis is relatively uncommon, accounting for less than 5% of all cases of acute pancreatitis, with numerous drugs being suggested as causative agents. 3,4 During the course of our patient’s disease, he received a combi- nation of at least 4  drugs that have been associated with acute pancreatitis (i.e., acetaminophen, dexamethasone, ciprofloxacin and pantoprazole), 3 in addition to tocilizumab, a known caus- ative agent.11 Two recent reports described patients with COVID- 19 who developed pancreatitis with hypertriglyceridemia (level of serum triglyceride  > 11.3  mmol/L) during treatment with a combination of tocilizumab and lopinavir/ritonavir.12,13 Although case reports cannot establish causality, our patient’s disease trajectory suggests that the manifestations of COVID-19 may include acute pancreatitis. Physicians should consider this possibility early or late in the course of COVID-19 illness. In addition, using personal protective equipment may com- promise the reliability of the physical examination of patients with COVID-19. Thus, unresolved abdominal pain warrants a thorough work-up, including testing for levels of amylase, lipase liver enzymes and triglycerides, and a complete blood cell count as an initial screening. If laboratory results are outside of normal ranges, clinicians may wish to consider further investigation with contrast-enhanced CT.

References

1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coro- navirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020 Feb. 24 [Epub ahead of print]. doi: 10.1001/jama.2020.2648. 2. Banks PA, Bollen TL, Dervenis C, et al.; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis — 2012: revision of the Atlanta classifi- cation and definitions by international consensus. Gut 2013;62:102-11. 3. Wolfe D, Kanji S, Yazdi F, et al. Drug induced pancreatitis: a systematic review of case reports to determine potential drug associations. PLoS One 2020; 15:e0231883. 4. Forsmark CE, Vege SS, Wilcox CM. Acute pancreatitis. N Engl J Med 2016;375: 1972-81. 5. Rawla P, Bandaru SS, Vellipuram AR. Review of infectious etiology of acute pancreatitis. Gastroenterology Res 2017;10:153-8. 6. Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol 2020 May 20 [Epub ahead of print]. doi:10.1002/path.5471. 7. Liu F, Long X, Zhang B, et al. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol 2020 Apr.  22 [Epub ahead of print]. S1542-3565(20)30537-1. doi:10.1016/j.cgh.2020.04.040. 8. Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology 2020 Apr.  1 [Epub ahead of print]. S0016-5085 (20)30409-1. doi:10.1053/j.gastro.2020.03.055. 9. Hadi A, Werge M, Kristiansen KT, et al. Coronavirus disease-19 (COVID-19) asso- ciated with severe acute pancreatitis: case report on three family members. Pancreatology 2020;20:665-7. 10. Anand ER, Major C, Pickering O, et al. Acute pancreatitis in a COVID-19 patient. Br J Surg 2020;107:e182. 11. Flaig T, Douros A, Bronder E, et al. Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System. J Clin Pharm Ther 2016;41:718-21. 12. Rubel AR, Chong PL, Abdullah MS, et al. Lipemic serum in patients with (coronavirus disease 2019) COVID-19 undergoing treatment. J Med Virol 2020 Apr.  28 [Epub ahead of print]. doi: 10.1002/jmv.25942. 13. Morrison AR, Johnson JM, Ramesh M, et al. Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab. J Med Virol 2020 Apr.  21 [Epub ahead of print]. doi: 10.1002/jmv.25907. Competing interests: None declared. This article has been peer reviewed. The authors have obtained patient consent. Affiliations: Departments of Internal Medicine E (Corona A) (Brikman, Denysova, Dori) and Surgery B (Menzal), HaEmek Medical Center, Afula, Israel; Faculty of Medicine (Brikman, Dori), Technion — Israel Institute of Technology, Haifa, Israel Contributors: Shay Brikman conceived the work and wrote the draft. Veronika Denysova, Husam Menzal and Guy Dori analyzed and inter- preted the data and revised the manuscript critically for important intellectual content. All of the authors gave final approval of the ver- sion to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Correspondence to: Shay Brikman, [email protected]

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-pdf ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

Coronavirus Infections Pancreatitis Pneumonia, Viral Betacoronavirus Coronavirus Infections Coronavirus Infections COVID-19 Humans Male Middle Aged Pancreatitis Pancreatitis Pancreatitis Pandemics Pneumonia, Viral Pneumonia, Viral SARS-CoV-2

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-11-15T09:34:25.365398+00:00
pubmed
last seen: 2026-10-12T06:16:15.384271+00:00
unpaywall
last seen: 2026-11-19T08:49:44.633026+00:00